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 A method for calculating effective lifetime risk of radiation-induced cancer 
from screening mammography 
Abstract 
Purpose: To propose a method for evaluating the effective lifetime risk of 
radiation-induced cancer from screening mammography and to present initial data 
for the UK National Breast Screening Programme. 
Material and methods: The imaging was undertaken using a Hologic Selenia full 
field digital mammographic unit. The proposed method utilises an ATOM phantom 
containing thermoluminescent dosimeters and a perspex-polyethylene breast 
phantom to measure organ doses during a standard four view screening 
mammogram. Effective dose was calculated and effective risk was modelled for a 
range of client ages. The total lifetime effective risk was then calculated for the UK 
national screening programme. Calculation of effective risk includes the radiation 
dose to examined and contralateral breasts in addition to other body organs; this is 
an advantage over the mean glandular dose. 
Results: The contralateral breast, thyroid, thymus, brain, lung, salivary glands, and 
bone marrow all receive more than 1µGy radiation dose during screening 
mammography. A major difference exists for total effective lifetime risk of 
radiation-induced cancer between clients with average and high breast cancer risk. 
Differences are attributed to the commencement age of screening and time interval 
between screens.  
Conclusion: This study proposes a method to evaluate effective lifetime risk of 
radiation-induced cancer from screening mammography in order to compare 
different mammography screening programmes.  
 
 




Medical imaging represents the major source of man-made ionizing radiation for 
people.1,2 In the United Kingdom (UK), mammography is the sixth largest source 
of ionizing radiation to the population from diagnostic imaging.3 However, the 
benefits of screening mammography are reported to outweigh the risks.4,5   
Since the glandular tissue is the most radiosensitive component of the breast tissue, 
the risk of radiation induced cancer from mammography is generally related to 
mean glandular dose (MGD).6 MGD is utilised as a standard quantity in breast 
dosimetry and is recommended by the International Commission on Radiological 
Protection (ICRP), the National Council on Radiation Protection (NCRP), and the 
Institute of Physics and Engineering in Medicine (IPEM). MGD can be used as a 
parameter to evaluate the mammographic system performance, patient risk 
assessment, and different mammographic imaging techniques.7 Accordingly, it is 
of great interest to a large number of researchers.5,8-12  
Surprisingly few investigators have considered the radiation dose received by body 
organs and tissues, other than the breast during mammography. They have 
investigated the dose to other tissues utilising mathematical models to simulate 
mammography.13-15 Direct measurement of the radiation dose to the skin overlying 
the thyroid has been investigated using thermoluminscent dosimeters (TLDs) 
during screening mammography.16 In the study by Whelan, McLean, and Poulos 
(16) they considered that the thyroid dose, which was 0.04 mGy, was insignificant 
compared to the 4 mGy dose received by the breast. Hatziioannou and colleages17 
also utilised TLDs, accommodated inside an upper body anthropomorphic lucite 
phantom for measurement of dose to the breast, sternum red bone marrow 
(SRBM), thyroid, liver, lung, stomach, and oesophagus during screening 
mammography. They found that the breast dose contributes over 98% of the 
overall effective dose. SRBM and thyroid receive a radiation dose between 0.4-
1.27 and 0.05-0.17 mGy/mAs, respectively, whereas the other organ doses were 
negligible. In summary, there is evidence to suggest that the radiation dose 
received by organs other than the breast requires further consideration as this dose 
and the risk associated with it is not captured by MGD. For a more thorough and 
accurate estimate of the risk from radiation during mammography, the dose to 
other organs should be taken into account. 
The internationally accepted method of estimating risk from an X-ray procedure is 
to use effective dose. Effective dose has enabled doses to be summed from whole 
and partial body exposure from external radiation of various types to estimate the 
risk of cancer development. Recently there is a new trend to replace effective dose 
by effective risk.18 Calculation of effective dose depends on tissue weighting 
factors which are regularly updated by ICRP based on the available evidence from 
epidemiological data.19 However, effective dose does not take into account an 
individual’s age or reproductive capacity. The effective lifetime risk of developing 
cancer is less for people who have 20 years to live compared to those who have 60 
years to live. Therefore, effective risk includes age, and gender lifetime-
attributable risk of cancer incidence per unit equivalent dose.18 
The lifetime attributable risk of radiation induced breast cancer from 
mammography has been calculated by Hendrick in 201020 and more recently by 
Yaffe and Mainprize in 2011.21 However, these authors did not progress their work 
to include the effective lifetime risk of radiation induced cancer from screening 
mammography. Based upon the UK National Health Service Breast Screening 
Programme (NHSBSP), our study proposes a new method for the calculation of 
effective lifetime risk of radiation induced cancer during screening mammography 
for females across the screening age range (47-73 years average risk clients and 
40-73 years high risk clients). 
Method 
This was an experimental approach for the calculation of effective lifetime risk of 
radiation-induced cancer from screening mammography for different client ages, 
from 40 to 73 years old. It required an accurate measurement of radiation dose 
received by the examined breast and other body tissues. 
A. Measurement of organ dose: 
280 Harshaw TLD-100H dosimeters (Thermo Scientific, USA) were placed inside 
a CIRS adult ATOM dosimetry phantom (CIRS Inc, Norfolk, Virginia, USA) to 
measure the absorbed radiation dose to tissues and organs during screening 
mammography (craniocaudal [CC] and mediolateral oblique [MLO] for each 
breast). TLDs-100H were chosen because they have high sensitivity, wide dose 
range (1pGy to 10Gy), and low fading rate.22 In order to avoid any residual charge, 
the TLDs were annealed at 240oC for 10 minutes before use. 
According to the European Commission23 the total uncertainty in dosimetric results 
by TLD should be less than 10%. Therefore, the TLDs sensitivity and consistency 
were established. In terms of sensitivity, all TLDs were exposed three times and 
according to their average response they were divided into five groups. The 
sensitivity difference for each group was less than 3%. For TLD consistency 
estimation, all TLDs were exposed and read three times with time intervals of 
around five days between the exposures then TLD responses were analysed using 
SPSS 20.0 (IBM, Armonk, New York, USA) to determine TLD consistency (Intra-
class Correlation-Consistency). The calculated consistency was 99%. 
Consequently, in our work, the total uncertainty of dose results was 4%. The 
average background signal of three unexposed TLDs was subtracted from the 
readings of exposed TLDs.24 As described by Tootell, Szczepura, and Hogg 
(2013)25, the TLDs were calibrated against Unfors Multi-O-Meter solid state 
detector (Billdal, Sweden) on three slabs (1cm thick each) of Perspex scatterer with 
beam quality the same as that which was used for dose measurement in the 
experiment, using the same mammography machine. Usually the calibration 
process is achieved for a complete batch because the calibration of each individual 
TLD is time consuming and shows minimal improvement in accuracy (the 
sensitivity difference of TLDs was less than 3%). For greater precision, the dose-
TLD response curve was utilised to obtain the TLD calibration factor.26 
A breast phantom described by Bouwman et al. (2013)27 was then used as standard 
breast. According to the design of this phantom, for simulating the standard breast, 
which is 53 mm thick, a 32.5 mm thick Poly Methyl Methacrylate (PMMA) and 
20.5 mm thick polyethylene (PE) slabs were used; the PE slabs were placed at the 
top of the phantom. The shape and area of PMMA-PE phantom depends on the 
mammographic projection of the simulated breast. For the average breast in CC 
projection, the shape of compressed breast is approximately semicircular with 
95mm radius. However, because the pectoral muscle is included in MLO 
projection a rectangular phantom with 100mm x 150mm was used with the 
required thickness of PMMA (32.5 mm) and polyethylene (25.5mm).28, 29 
The ATOM and breast phantoms were positioned on a Hologic Selenia full field 
digital mammography system (Bedford, USA) to simulate the real woman’s 
position during screening mammography. 
For MLO position simulation, firstly, the gantry was tilted 47o. This value of 
angulation is determined depending on ATOM phantom body contour. Secondly, 
the MLO phantom was centered on the detector in the chest wall side and the 
compression paddle was used to fix it in position. Thirdly, the ATOM phantom 
was arranged in contact with the breast phantom where the midpoint in the side of 
the breast phantom coincides with the centre point in the breast site on the ATOM 
phantom. The detector was placed against the ribs with its corner in the axilla. 
The CC position was achieved with the X-ray beam perpendicular to the floor. 
Initially, the CC breast phantom was centred on the detector in the chest wall side 
and fixed in position by the compression paddle. The midpoint in the side of the 
breast phantom was arranged to coincide with the centre point in the breast site on 
the ATOM phantom, which faced the mammography system.30 
Since automatic exposure control (AEC) is the most commonly used technique in 
screening mammography, it was adopted to expose the breast phantom. For each 
position the phantom was exposed three times and then averaged (CC and MLO 
for each breast) to minimise random error. TLDs were then collected and read in a 
Harshaw 3500 TLD reader (Thermo Scientific, USA). Using the manufacturer’s 
TLD location map31, radiation absorbed dose of each organ was calculated by 
averaging the radiation dose values inside the organ. In addition to contralateral 
breast, doses received by 19 other organs were measured. The numbers of TLDs 
used for each organ are listed in (Table 1). The whole process was repeated three 








Table 1  
The number of TLDs utilised for dose measurement inside each organ. 
Organ No. of TLDs Organ No. of TLDs 
Adrenal 2 Pancreas  5 
Brain 11 Pelvis BM 17 
Clavicle BM 4 Ribs BM 18 
Cranium BM 4 Scapulae BM 16 
C-spine BM 2 Spleen  12 
Gall bladder 5 Sternum BM 4 
Heart  2 Stomach  14 
Intestine  15 T/L spine BM 8 
Kidneys  16 Thymus  4 
Liver  29 Thyroid  6 
Lungs  36 Urinary Bladder (UB) 16 
Mandible BM 6 Contralateral breast  8 
Oesophagus  3 Salivary gland  6 
Ovaries  2 Uterus 9 
 
B. Estimation of examined breast dose: 
MGD was calculated using the method recommended by IPEM (Report 89)32 and 
using the following equation: 
MGD=K.g53.c53.s 
Where K is the entrance air kerma for the phantom, g53 is a factor to convert the 
incident air kerma to MGD for 53mm thick standard breast, c53 is a conversion 
factor which allows for the glandularity of 53mm thick standard breast, s is the 
spectral correction factor. The values for the above factors are listed in the same 
report for each half-value layer (HVL). 
In our study the HVL of the mammographic X-ray beam was assessed according to 
the procedure described by Moore et al. (2005)32 in IPEM report 89. An Unfors 
solid state dosimeter and high purity aluminum foils of thickness ranging from 
0.1mm to 0.6mm were used. The foils were placed infront of the X-ray beam 
window with the compression paddle midway between the foils and detector. 
Then, as recommended by the European Commission23, the HVL was graphically 
derived by an interpolation method. This was done by plotting the detector 
readings algorithms against the relevant foil thickness. For mammographic X-ray 
beams used in CC and MLO views, the estimated values of HVL were 0.4 and 
0.5mm Al, respectively.  
C. Radiation effective risk estimation: 
The effective risk was calculated by using the equation described by Brenner 
(2009).18 
R=∑rTHT 
Where R is the effective risk, rT is the lifetime cancer risk for tissue T per unit 
equivalent dose of that tissue, and HT  is the equivalent dose for tissue T. 
The attributable lifetime cancer risk of different tissues (rT) are taken from BEIR 
VII – Phase 2 report of National Academy of Sciences.33 Because these values are 
presented for each decade of female age (see Table 2), they were plotted against 
age to obtain the value for each year of female life see (Figure 1) for the breast. A 
line for best fit was created (y=0.13x2-19.074x+703.09, R2=0.9959) to determine 
risk for years 41-49, 51-59, 61-69, and 71-79 inclusive. The same method was used 
for each type of tissue. 
Table 2  
Lifetime attributable risk of radiation induced cancer for tissues which received 
radiation dose during screening mammography for each decade of female age as 
listed in Table 12D-1 of the 2006 BEIR-VII report.33 
Tissue 
Risk coefficient (cases /10,000 persons /Gy) at different ages 
40 50 60 70 80 
Breast 141 70 31 12 4 
Stomach 35 32 27 19 11 
Liver 10 9 7 5 2 
Lung 240 230 201 147 77 
Thyroid 14 4 1 0.3 0 





Figure 1. Lifetime attributable risk of radiation induced cancer in breast tissue for 
women aged 30-80 years. 
 
Results  
Examined breast MGD along with radiation absorbed dose for other 20 organs, 
from one screening visit, are recorded in (Table 3). It provides evidence that some 
organs did not receive a radiation dose during screening mammography. However, 















Organ radiation dose from one screening visit (4 views). 
Organ 
Dose 1  
(µGy) 




Average dose  
(SD) (µGy) 
Brain 1.312 1.108 1.538 1.320 (0.21) 
Salivary glands  3.825 2.714 2.143 2.894 (0.86) 
Thyroid 10.421 9.527 8.573 9.507 (0.92) 
Oesophagus  0.340 0.221 0.245 0.269 (0.06) 
Thymus 3.180 2.278 2.062 2.506 (0.59) 
Heart 0.488 0.373 0.296 0.386 (0.10) 
Lung 2.942 2.611 2.457 2.670 (0.25) 
Liver 0.477 0.564 0.461 0.501 (0.06) 
Gall bladder 0.103 0.054 0.055 0.071 (0.03) 
Adrenal 0.302 0.541 0.350 0.398 (0.13) 
Kidney 0.086 0.074 0.103 0.088 (0.01) 
Spleen 0.128 0.027 0.018 0.058 (0.06) 
Pancreas 0.005 0.004 0.008 0.006 (0.00) 
Stomach 0.315 0.284 0.492 0.363 (0.11) 




Cranium  2.552 1.541 2.439 2.177 (0.55) 
Mandible  3.325 2.714 2.643 2.894 (0.37) 
C-spine  1.020 0.524 0.541 0.695 (0.28) 
Clavicle  10.408 11.652 12.963 11.674 (1.28) 
Scapulae  0.298 0.276 0.282 0.285 (0.01) 
Sternum  14.092 15.378 16.021 15.164 (0.98) 
Ribs  3.466 3.172 3.043 3.227 (0.22) 
T/L spine  0.256 0.100 0.137 0.164 (0.08) 
Pelvis  0.000 0.000 0.000 0.000 (0.00) 
Total BM dose (63.5%)* 1.420 1.276 1.365 1.353 (0.07) 
Urinary bladder 0.000 0.000 0.000 0.000(0.00) 
Uterus  0.000 0.000 0.000 0.000(0.00) 
Ovaries  0.000 0.000 0.000 0.000(0.00) 
Contralateral breast 25.941 28.705 25.102 26.583 (1.89) 
Examined breast (MGD) 2681.000 2674.000 2685.000 2680.000 (5.57) 
* This percent represents the portion of bone marrow (BM) received radiation dose during 
mammography. It is adapted from ICRP report 70 (1995) and it is distributed as 0.8% in 
clavicle, 7.6% in cranium, 3.9%in C-spine, T/L spine (28.4%), 0.8% in mandible, 16.1% in ribs, 
2.8% in scapula, and 3.1% in sternum.34 
 
The effective dose in µSv was calculated for one screening event (four views) 
depending on the latest tissue weighting factors that have been recommended by 
ICRP (2007).35 The generated data of this calculation are presented in (Table 4) 
together with absorbed dose of individual organs. 
Table 4  
Tissue weighting factor, mean organ dose, and weighted dose used to calculate 
female effective dose (ED) from one four-view screening mammography 








Bone marrow 0.12 1.353 (0.07) 0.162 
Colon  0.12 0.000 (0.00) 0.000 
Lung  0.12 2.670 (0.25) 0.320 
Stomach  0.12 0.363 (0.11) 0.044 
Ovaries  0.08 0.000 (0.00) 0.000 
Bladder  0.04 0.000 (0.00) 0.000 
Oesophagus  0.04 0.269 (0.06) 0.011 
Liver  0.04 0.501 (0.06) 0.020 
Thyroid  0.04 9.507 (0.92) 0.380 
Brain  0.01 1.320 (0.21) 0.013 
Salivary glands 0.01 2.894 (0.86) 0.029 
Other  0.12 0.390 (0.08) 0.047 
Contralateral breast 0.12 26.583 (1.89) 3.190 
Examined breast (MGD) 
(2 view) 
0.12 2680.000 (5.57) 321.6 
Mean ED (SD) = 325.816 (0.67) (µSv) 
 
Because of the continuous decline in human tissue radio-sensitivity with age 
(Figure1), the effective risk from screening mammography reduces with increasing 







Table 5  
Radiation effective risk of one screening mammography event (4view) for female 
aged 40-73years.  
Age 
(year) 
Cancer incidence in different tissues (case/106) Effective risk 
(sd) 





40 0.001 0.000 0.065 0.012 0.015 39.699 0.394 40.187 (0.05) 
41 0.001 0.000 0.065 0.011 0.015 37.409 0.371 37.873 (0.05) 
42 0.001 0.000 0.065 0.009 0.015 35.189 0.349 35.629 (0.05) 
43 0.001 0.000 0.065 0.008 0.014 33.039 0.328 33.455 (0.05) 
44 0.001 0.000 0.064 0.007 0.014 30.958 0.307 31.352 (0.04) 
45 0.001 0.000 0.064 0.006 0.014 28.947 0.287 29.320 (0.04) 
46 0.001 0.000 0.064 0.006 0.014 27.005 0.268 27.358 (0.04) 
47 0.001 0.000 0.063 0.005 0.013 25.134 0.249 25.466 (0.03) 
48 0.001 0.000 0.063 0.004 0.013 23.332 0.231 23.645 (0.03) 
49 0.001 0.000 0.062 0.004 0.013 21.599 0.214 21.894 (0.03) 
50 0.001 0.000 0.062 0.003 0.012 19.937 0.198 20.213 (0.03) 
51 0.001 0.000 0.061 0.003 0.012 18.344 0.182 18.603 (0.03) 
52 0.001 0.000 0.060 0.003 0.012 16.820 0.167 17.063 (0.02) 
53 0.001 0.000 0.059 0.002 0.012 15.367 0.152 15.594 (0.02) 
54 0.001 0.000 0.059 0.002 0.011 13.983 0.139 14.195 (0.02) 
55 0.001 0.000 0.058 0.002 0.011 12.668 0.126 12.866 (0.02) 
56 0.001 0.000 0.057 0.002 0.011 11.424 0.113 11.608 (0.02) 
57 0.001 0.000 0.056 0.001 0.010 10.249 0.102 10.420 (0.01) 
58 0.001 0.000 0.055 0.001 0.010 9.144 0.091 9.302 (0.01) 
59 0.001 0.000 0.054 0.001 0.010 8.108 0.080 8.255 (0.01) 
60 0.001 0.000 0.053 0.001 0.009 7.142 0.071 7.278 (0.01) 
61 0.001 0.000 0.052 0.001 0.009 6.246 0.062 6.371 (0.01) 
62 0.001 0.000 0.051 0.001 0.009 5.419 0.054 5.535 (0.01) 
63 0.001 0.000 0.049 0.001 0.008 4.663 0.046 4.769 (0.01) 
64 0.001 0.000 0.048 0.001 0.008 3.976 0.039 4.073 (0.01) 
65 0.001 0.000 0.047 0.001 0.008 3.358 0.033 3.447 (0.01) 
66 0.001 0.000 0.045 0.000 0.007 2.810 0.028 2.892 (0.01) 
67 0.001 0.000 0.044 0.000 0.007 2.332 0.023 2.408 (0.01) 
68 0.001 0.000 0.042 0.000 0.007 1.924 0.019 1.993 (0.01) 
69 0.001 0.000 0.041 0.000 0.006 1.585 0.016 1.649 (0.00) 
70 0.001 0.000 0.039 0.000 0.006 1.316 0.013 1.376 (0.00) 
71 0.001 0.000 0.038 0.000 0.006 1.116 0.011 1.172 (0.00) 
72 0.001 0.000 0.036 0.000 0.005 0.987 0.010 1.039 (0.00) 
73 0.001 0.000 0.034 0.000 0.005 0.927 0.009 0.976 (0.00) 
 
The total radiation effective risk, during a female’s lifetime, is generally related to 
the age of screening commencement and time interval between the successive 
screens. Data for ‘average’ and ‘high risk’ NHSBSP clients are presented in (Table 
6). 
Table 6  
Total effective risk (during woman life) of screening mammography according to 



























The objective of screening mammography is to detect breast cancer early when 
treatment and recovery are more likely to be successful. However, since the 
introduction of screening mammography there has been great debate about the 
risks versus benefits. In this context, Jin (2014)37 reported the possible 
disadvantages of screening mammography, other than the radiation risk. These 
drawbacks were: firstly, the false negative which is mammography’s inability to 
detect all breast cancers; secondly, mammography false positive (wrong diagnosis) 
which results in time wasted in extra examinations and undesired anxiety; thirdly, 
over diagnosis, the treatment of low risk breast cancers which would not cause 
health problems. 
To understand the radiation risk associated with mammography many researchers 
have focused on screening mammography. The majority of researchers used mean 
glandular dose as a parameter to quantify the radiation risk. In contrast others 
utilised women-years of life lost due to radiation induced cancer from screening 
mammography. Our work uses the effective risk of radiation induced cancer as a 
parameter to assess mammography radiation risk. The method of effective risk 
calculation is relatively easy to perform, takes age into account and generates data 
that are more understandable to the general public when compared to MGD.  
However, there are several limitations with our method. Firstly, a single size body 
phantom was used and this limits the generalisability of our calculations to average 
size women only. Secondly, there will be error associated with the fitting process 
(y=0.13x2-19.074x+703.09) of life time attributable risk to adjust for unpublished 
data for each year of the life. Thirdly, only the average female breast has been 
considered in our study. Other breast thicknesses and compositions were not 
considered, this should be addressed in future research. 
Female breasts have different sizes and densities, the latter changes with age. 
Consequently our method can be extended by using different sizes of human body 
phantoms and breast phantoms of different thicknesses and densities. For instance, 
to simulate small dense breast, which has a 20 mm thickness and 97% density, a 20 
mm PMMA have to be used. On the contrary, 37.5 mm PMMA and 62.5mm PE 
can be utilised to simulate thick fatty breast that has 100 mm thickness and 3% 
glandularity (27).  
The comparison of different categories of NHSBSP, in terms of total effective risk, 
(Table 6) illustrates that the total effective risk of high breast cancer risk client is 
about 5 times more than that of average risk client. NHSBSP was used to illustrate 
data arising from our method, we propose that our method be applied to different 
screening programmes world-wide and also different mammography machines so 
that effective risk comparisons can be made. 
Conclusion 
A new method has been developed to quantify the risk of radiation induced cancer 
(effective risk) from screening mammography. This method can be used to 
compare international mammography screening programmes. High breast cancer 
risk clients have higher effective risk from radiation than those with average breast 
cancer risk. Effective risk should be taken into account when mammography 
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